These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24744598)

  • 1. Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.
    Wang KL; Xing HQ; Zhao H; Liu JW; Gao DL; Zhang XH; Yao HY; Yan L; Zhao J
    World J Gastroenterol; 2014 Apr; 20(14):4071-5. PubMed ID: 24744598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
    Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
    J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of pegylated interferon alpha-2a in HCV-positive hemodialysis patients.
    Ucmak H; Kokoglu OF; Hosoglu S; Dogan E; Sayarlioglu H; Kuzhan N; Isik IO
    Ren Fail; 2008; 30(2):227-32. PubMed ID: 18300126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Kokoglu OF; Uçmak H; Hosoglu S; Cetinkaya A; Kantarceken B; Buyukbese MA; Isik IO
    J Gastroenterol Hepatol; 2006 Mar; 21(3):575-80. PubMed ID: 16638102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A; Maftei ID; Mardare NG; Ioniţă-Radu F; Totolici C; Tuţă L; Golea O; Covic M; Volovăţ C; Gusbeth-Tatomir P; Mircescu G
    J Nephrol; 2006; 19(6):794-801. PubMed ID: 17173254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
    World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.
    Amarapurkar DN; Patel ND; Kirpalani AL
    Trop Gastroenterol; 2007; 28(1):16-8. PubMed ID: 17896604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.
    Köse Ş; Senger SS; Ersan G; Çavdar G
    Clin Exp Nephrol; 2013 Feb; 17(1):115-9. PubMed ID: 22814955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.
    Ayaz C; Celen MK; Yuce UN; Geyik MF
    World J Gastroenterol; 2008 Jan; 14(2):255-9. PubMed ID: 18186564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1.
    Dogan UB; Atabay A; Akin MS; Yalaki S
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C.
    Yada M; Masumoto A; Yamashita N; Motomura K; Koyanagi T; Sakamoto S
    World J Gastroenterol; 2010 Mar; 16(12):1506-11. PubMed ID: 20333792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Kondo Y; Inoue J; Matsuda Y; Kakazu E; Yamamoto T; Onodera H; Miyazaki Y; Okamoto H; Akahane T; Kobayashi T; Mano Y; Iwasaki T; Ishii M; Shimosegawa T
    World J Gastroenterol; 2008 Dec; 14(47):7225-4230. PubMed ID: 19084938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.